[SCHEDULE 13G/A] Kintara Therapeutics, Inc. Common Stock SEC Filing

Rhea-AI Filing Summary

KP Biotech Group LLC reported beneficial ownership of 447,232 shares of TuHURA Biosciences, Inc. common stock, representing 0.9% of the outstanding class. The filing states these shares confer sole voting and sole dispositive power over all 447,232 shares and that the stake was not acquired to influence control of the issuer. The percent ownership is calculated using an outstanding share count of 50,046,926 shares reported by the issuer. The filing is a Schedule 13G amendment and affirms the position is below the 5% ownership threshold that would trigger more extensive disclosure.

Positive

• Clear disclosure of beneficial ownership with exact share count (447,232) and voting/dispositive powers
• Position below 5% (0.9%), indicating passive investor status and no reported intent to influence control
• Filing certified by an authorized manager, providing formal compliance with reporting rules

Negative

• None.

Insights

Financial Analyst

TL;DR: A small, passive stake under 1% with sole voting and dispositive power; not material to control or valuation.

The reporting person holds 447,232 shares, equal to 0.9% of TuHURA's common stock based on the issuer's stated share count. That position is below the 5% reporting threshold for Schedule 13D treatment and is filed on Schedule 13G/A, which typically indicates a passive investor. The filing expressly certifies the shares were not acquired to change or influence control. For investors, this is a disclosure of ownership rather than an operational or strategic development; it does not alter capital structure or signal an activist intent.

Corporate Governance Expert

TL;DR: Ownership is disclosed as passive and below material control levels; governance impact is negligible.

The document records that KP Biotech Group LLC has sole voting and dispositive power over the reported shares but affirms no intent to influence control. Because the stake is below 5% and the filer elected Schedule 13G treatment, this is consistent with passive disclosure obligations. There are no group affiliations, no shared powers, and no indications of coordinated action. From a governance perspective, this filing does not change board control dynamics or trigger governance reviews.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

TuHURA Biosciences, Inc.

(Name of Issuer)

Common Stock, par value $0.001 per share

(Title of Class of Securities)

898920103

(CUSIP Number)

06/12/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 898920103

1

Names of Reporting Persons

KP Biotech Group LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 447,232.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 447,232.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

447,232.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0.9 %

12

Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person: Includes 447,232 shares of common stock, par value $0.001 per share ("Common Stock"), of the Issuer. *Percent of class is calculated based on 50,046,926 shares of Common Stock outstanding as of August 11, 2025, as reported by the Issuer in its Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission on August 14, 2025. The percentage of ownership was calculated in accordance with Rule 13d-3(d)(1)(i) promulgated under the Securities Exchange Act of 1934, as amended.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: TuHURA Biosciences, Inc.
(b)	Address of issuer's principal executive offices: 10500 University Drive, Suite 110, Tampa, Florida, 33612
Item 2.
(a)	Name of person filing: KP Biotech Group LLC
(b)	Address or principal business office or, if none, residence: The business address of the Reporting Person is 5600 Mariner St., Ste. 200, Tampa, FL 33609.
(c)	Citizenship: KP Biotech Group LLC is a Florida limited liability company.
(d)	Title of class of securities: Common Stock, par value $0.001 per share
(e)	CUSIP No.: 898920103
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: Amount Beneficially Owned: As of June 12, 2025, the Reporting Person beneficially owns 447,232 shares of Common Stock, representing less than 5% of the class outstanding.
(b)	Percent of class: Percent of Class: 0.9%. Percent of class is calculated based on 50,046,926 shares of Common Stock of the Issuer outstanding as of August 11, 2025, as reported by the Issuer in its Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission on August 14, 2025. The percentage of ownership in this Item 4 was calculated in accordance with Rule 13d-3(d)(1)(i) promulgated under the Securities Exchange Act of 1934, as amended.
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 447,232
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 447,232
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

KP Biotech Group LLC

Signature:	/s/ Adam Baals
Name/Title:	Adam Baals, Manager
Date:	08/14/2025

FAQ

How many TuHURA Biosciences (common stock) shares does KP Biotech Group LLC report owning?

The filing reports 447,232 shares of TuHURA Biosciences common stock.

What percentage of TuHURA's class does the reported stake represent?

The stake represents 0.9% of the outstanding common stock, calculated using 50,046,926 shares outstanding.

Does KP Biotech Group LLC claim voting or dispositive power over the shares?

Yes. The filer reports sole voting power and sole dispositive power for all 447,232 shares.

Was the stake acquired to influence control of TuHURA Biosciences?

No. The certification states the securities were not acquired and are not held for the purpose of changing or influencing control of the issuer.

What type of SEC form is this filing and what does that indicate?

This is a Schedule 13G/A (amendment), which typically indicates a passive investor disclosing ownership below material control thresholds.